Minoxidil for Androgenetic Alopecia

Verdict: Strong, proven treatment for pattern hair loss

Topical minoxidil genuinely works for androgenetic alopecia (male and female pattern hair loss), with consistent high-quality trial evidence and unanimous regulator and clinic backing placing it among the best-supported options. The catch is that it only maintains results while you keep using it, works best on the crown rather than the hairline, and not everyone responds.

S 🟢 S Strong Evidence Published

🔬Why this grade7-layer evidence engine

This earns the top Strong-Evidence (S) grade because the proof is unusually consistent and convergent. A meta-analysis of treatments for androgenetic alopecia (PMID 28396101) found both 5% and 2% topical minoxidil significantly outperformed placebo in men, and 2% in women, with P<0.00001 across all three comparisons. A 2026 systematic review (PMID 41695992) confirms topical minoxidil remains the only FDA-approved treatment for both sexes, and a 2025 meta-analysis (PMID 41127390) treats minoxidil monotherapy as the established active baseline that combination therapy is measured against.

Regulators and major clinics line up behind the trial data with no real dissent. The US FDA label approves it to regrow hair on the top (vertex) of the scalp; Mayo Clinic and Cleveland Clinic list it as the usual first-line option; Harvard Health states that 'only minoxidil and finasteride have been proven useful'; and the EADV specialty guideline gives it the strongest 'We recommend' rating at Level 1 evidence. This three-way agreement among trials, regulators, and clinics is what pushes it to S tier.

The grade reflects real benefit, not a cure. Regrown hair is lost within a few months of stopping, so it requires indefinite use; results are best at the crown rather than the frontal hairline; and a meaningful minority are non-responders. A separate dose-response meta-analysis of low-dose oral minoxidil (PMID 36161084) shows it also works (about +47 hairs/cm2 per mg/day) but is off-label, with cardiovascular and excess-hair side effects rising with dose.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable

Raw score 0.78

← counter-evidence / ineffectiveeffective / strong evidence →

Final grade

S · Published

Confidence

91%

Highly consistent evidence

Evidence level

Multiple high-quality MAs (≥2 independent, consistent)

How strongly each layer supports this effect

lower = less supportive

L1 ExamineGlobal benchmark

0.50

L3 MechanismPlausibility

0.65

L2 PubMedPrimary literature

0.85

L5 Clinical bodiesAuthoritative stance

0.85

L11 AI re-checkIndependent read

0.95

Against Mixed Supports

▸View the full decision path (audit trail)

compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.775
tier_from_score — 依分數區間映射至 tier letter
apply_hec_rules — 高品質 SR/MA 顯示 positive (4 篇 > 1 negative)
tier_strict_requirement_check — A 級條件達標
detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (9)L2 · primary research & systematic reviews

Topical Minoxidil: Systematic Review and Meta-Analysis of Its Efficacy in Androgenetic Alopecia

PMID: 26380504 2015 統合分析

Finding: Random-effects meta-analysis found topical minoxidil significantly more effective than placebo for total and nonvellus hair growth and for investigator/patient-rated improvement, though cosmetically acceptable results occurred in only a subset of patients.

🟢 High quality Effect size: MD 16.68 (95% CI 9.34-24.03) total hair count; MD 20.90 (95% CI 9.07-32.74) nonvellus hair; RR 2.28 (95% CI 1.58-3.31) investigator assessment

View on PubMed

Relative Efficacy of Minoxidil and the 5-α Reductase Inhibitors in Androgenetic Alopecia Treatment of Male Patients: A Network Meta-analysis

PMID: 35107565 2022 Network Meta-analysis

Finding: Bayesian network meta-analysis of 23 studies compared minoxidil with 5-alpha reductase inhibitors; authors concluded relative efficacy remains unsettled pending more head-to-head trial data.

View on PubMed

The effectiveness of treatments for androgenetic alopecia: A systematic review and meta-analysis

PMID: 28396101 2017 統合分析

Finding: Meta-analyses across five nonsurgical treatment groups found all treatments, including minoxidil, superior to placebo for hair growth outcomes in men, and minoxidil effective in women.

🟢 High quality Effect size: P < .00001 across the 5 meta-analyses

View on PubMed

Efficacy of non-surgical treatments for androgenetic alopecia: a systematic review and network meta-analysis

PMID: 29797431 2018 Network Meta-analysis

Finding: Across 22 studies with usable NMA data, minoxidil 2% and 5% produced hair-count gains approximately equivalent to finasteride and dutasteride, though the quality of evidence for minoxidil vs placebo comparisons was rated low.

🟠 Limited quality

View on PubMed

A randomized clinical trial of 5% topical minoxidil versus 2% topical minoxidil and placebo in the treatment of androgenetic alopecia in men

PMID: 12196747 2002 RCT (double-blind) n = 393

Finding: 5% topical minoxidil produced significantly greater hair regrowth than 2% minoxidil and placebo over 48 weeks in men with AGA.

🟢 High quality Effect size: 45% more hair regrowth with 5% vs 2% minoxidil at week 48

View on PubMed

A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss

PMID: 15034503 2004 RCT (double-blind) n = 381

Finding: 5% topical minoxidil was superior to placebo across all three primary efficacy measures in women with female pattern hair loss, and superior to 2% minoxidil on patient-assessed benefit at week 48, though with more scalp irritation and hypertrichosis.

🟢 High quality

View on PubMed

Oral Minoxidil vs Topical Minoxidil for Male Androgenetic Alopecia: A Randomized Clinical Trial

PMID: 38598226 2024 RCT (double-blind) n = 68

Finding: Oral minoxidil 5 mg/day did not demonstrate superiority over topical minoxidil 5% twice daily for treating male AGA over 24 weeks.

🟢 High quality Academic

View on PubMed

Combination Therapy in Androgenetic Alopecia: A Network Meta-Analysis of Minoxidil and Other Pharmacological Agents

PMID: 42168420 2026 Network Meta-analysis n = 3,012

Finding: Across 27 RCTs, minoxidil combined with spironolactone, flutamide, PRPF, or finasteride ranked highest for treatment outcomes, though the authors caution the evidence base needs more high-quality, multicenter confirmation.

View on PubMed

Efficacy and safety of oral minoxidil versus topical solution in androgenetic alopecia: a meta-analysis of randomized clinical trials

PMID: 39425514 2025 統合分析 n = 279

Finding: Pooling 4 RCTs (279 patients), oral and topical minoxidil showed statistically similar efficacy and safety, with equivalent improvements in hair density/diameter and equivalent overall adverse-event rates, though hypertrichosis was more common with oral minoxidil.

Effect size: Hypertrichosis RR 2.01 (oral vs topical); no significant difference in hair density/diameter

View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA

Supportive

to regrow hair on the top of the scalp (vertex only, see pictures on side of carton) source↗

L4c UK NHS

Supportive

L4d TW TFDA / 衛福部

Supportive

醫師藥師藥劑生指示藥品 source↗

L5b Mayo Clinic

Supportive

Minoxidil (Rogaine). Over-the-counter (nonprescription) minoxidil comes in liquid, foam and shampoo forms. To be most effective, apply the product to the scalp skin once daily for women and twice daily for men. Many people prefer the foam applied when the hair is wet. Products with minoxidil help many people regrow their hair or slow the rate of hair loss or both. source↗

L5c Cleveland Clinic

Supportive

Over-the-counter (OTC) medications you apply to your scalp, such as minoxidil (Rogaine®), are usually the first course of treatment for male pattern baldness. Minoxidil may take two to four months of daily use before you notice any improvement in your hair loss. If you stop using either medication, your regrown hair will fall out. source↗

L5d Harvard Health

Supportive

only minoxidil and finasteride have been proven useful source↗

L5e Specialty Society (condition-mapped)

Supportive

Topical Minoxidil 2-5% solution 1 mL or half a cap of 5% foam twice daily is recommended to improve or to prevent progression of AGA in male patients above 18 years with mild to moderate AGA (Hamilton-Norwood IIv-V). [Strength of recommendation: ↑↑ 'We recommend'; Level of evidence 1] source↗

📰Related guidesEditorial coverage citing this evidence · 4 articles

✓PMID 100% verifiedevery citation checked via NCBI Entrez

🔬9 PubMed studiesindependently re-checked by multiple sub-agents

engine_version: v1.0 claim_id: CLM-COND-androgenetic-alopecia-INT-minoxidil-001 繁體中文版 →